

*Duplicate***Ladas & Parry**

Los Angeles Office
5670 Wilshire Boulevard, 21st Floor
Los Angeles, California 90036

Fax Cover Sheet

Fax: (323) 934-0202
Phone: (323) 934-2300

To: Ulrike Winkler
c/o USPTO

Facsimile No. (703) 746-3162

From: Tomas Lendvai

Date: October 4, 2002

Pages: 12 (including this page)

Subject: Our Reference: 618769-8 B-4775 PCT

THIS MESSAGE IS INTENDED ONLY FOR USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION WHICH IS PRIVILEGED, CONFIDENTIAL OR OTHERWISE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by fax or telephone and return the original message to us at the above address via mail. We will cheerfully refund your reasonable out-of-pocket expenses. Thank You.

MESSAGE: Pursuant to our conversation of today, attached please find the relevant copies of PCT Application No. PCT/IT99/00356.

EL652176619USIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stefano COLLOCA) Re: Preliminary Amendment
U.S. Appln. No.: not yet)
assigned) Group: not yet assigned
U.S. Filing Date: concurrently) Examiner: not yet assigned
herewith)
International Application No:)
PCT/IT99/00356)
International Filing Date:) Our Ref.: B-4175PCT 618769-8
8 November 1999)
For: "CELLS FOR THE PRODUCTION)
OF HELPER DEPENDENT ADENOVIRAL)
VECTORS, METHOD FOR THE)
PREPARATION AND USE THEREOF") Date: May 4, 2001

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Attn: United States Designated/Elected Office (DO/EO/US)

Sir:

Prior to examination of the above-identified application, it is respectfully requested that the following amendments be made to the claims:

IN THE CLAIMS

Please replace Claims 7-10, 15-18, 20, 22-24, and 27 with new amended Claims 7-10, 15-18, 20, 22-24, and 27, which are set forth below. (Appendix A, which is enclosed herewith, shows how Claims 7-10, 15-18, 20, 22-24, and 27 were amended to produce new amended Claims 7-10, 15-18, 20, 22-24, and 27.)

7. (Amended) Cells according to claim 4, wherein said virus is Epstein-Barr virus, the origin of replication is OriP and the activating factor is EBNA-1.